Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype

Human Pathology

Volumn 29, Issue 3, 1998, Pages 246-251

  Beer, Trevor W ^a   Buchanan, Rose ^b   Matthews, Alan W ^b   Stradling, Robin ^b   Pullinger, Neil ^b   Pethybridge, Roger J ^b  

^a Royal Hospital   (United Kingdom)

^b NONE

Author keywords

Malignant mesothelioma; MIB 1; Prognosis; Proliferation

Indexed keywords

CYCLINE; KI 67 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MITOSIS INDEX; PROGNOSIS;

EID: 0031917134     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90043-0     Document Type: Article

References (35)

1. Peto J, Hodgson JT, Matthews FE, et al: Continuing increase in mesothelioma mortality in Britain. Lancet 345:535-539, 1995
2. Veys CA: ABC of Work Related Disorders: Occupational Cancers. Br Med J 313:615-619, 1996
3. Alberts AS, Falkson G, Goedhals L, et al: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527-535, 1988
4. Branscheid D, Krysa S, Bauer E, et al: Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothoracic Surg. 5:466-472, 1991
5. Schildge J, Kaiser D, Henss H, et al: Prognostic factors in diffuse malignant mesothelioma of the pleura. Pneumologie 43:660-664, 1989
6. Boutin C, Rey F, Gouvernet J, et al: Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72:394-404, 1993
7. Boutin C, Viallat JR, Rey F, et al: Diagnosis and prognosis of malignant mesothelioma. Rev Pract 40:1846-1850, 1990
8. Hulks G, Thomas JS, Waclawski E: Malignant pleural mesothelioma in western Glasgow 1980-6. Thorax 44:496-500, 1989
9. De Pangher Manzini V, Brollo A, Franceschi S, et al: Prognostic factors of malignant mesothelioma of the pleura. Cancer 72:410-417, 1993
10. Martensson G, Hagmar B, Zettergren L: Diagnosis and prognosis in malignant mesothelioma: A prospective study. Eur J Respir Dis. 65:169-178, 1984
11. Ramael M, Jacobs W, Weyler J, et al: Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol 172:247-253, 1994
12. Gerdes J, Lemke H, Wacker HH, et al: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
13. Kamel OW, Franklin WA, Ringus JC, et al: Thymidine labelling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol 134:107-113, 1989
14. McCormick D, Yu C, Hobbs C, et al: The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology 22:543-547, 1993
15. McCormick D, Chong H, Hobbs C, et al: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 22:355-360, 1993
16. Brown DC, Gatter KC: Monoclonal antibody Ki-67: Its use in histopathology. Histopathology 17:489-503, 1990
17. Jain S, Filipe MI, Hall PA, et al: Proliferating cell nuclear antigen (PCNA): prognostic value in gastric carcinoma. J Clin Pathol 44:655-659, 1991
18. Querzoli P, Albonico G, Ferretti S, et al: MIB 1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol, 49:926-930, 1996
19. Weiss SW: Histological typing of soft tissue tumours (ed 2). World Health Organisation, Geneva, Springer, 1994, pp 36-37
20. Enzinger FM, Weiss SW: Soft tissue tumours (ed 3). St Louis, Mosby, 1995, pp 787-819
21. Peto R, Peto J: Asymptotically Efficient Rank Invariant Procedures. Royal Stat Soc 135:185-207, 1972
22. Ansari B, Coates PJ, Greenstein BD, et al: In-situ end labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170:1-8, 1993
23. McCormick D, Hall P: The Complexities of proliferating cell antigen. Histopathology 21:591-594, 1992
24. Jain S, Filipe M, Hall P: Proliferating cell nuclear antigen (PCNA): Prognostic value in gastric carcinoma. J Clin Pathol 44:655-659, 1991
25. Pinder SE, Wencyk P, Sibbering DM, et al: Assessment of the new proliferation marker MIB 1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. Br J Cancer 71:146-149, 1995
26. Walz R, Koch HK: Malignant pleural mesothelioma: Some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985. Pathol Res Practice 186:124-134, 1990
27. Hillerdal G: Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 77:321-343, 1983
28. Hoekman K, Tognon G, Risse EK, et al: Well-differentiated papillary mesothelioma of the peritoneum. A separate entity. Eur Jol Cancer, 32:255-258, 1996
29. Norman PE, Whitaker D: Nine-year survival in a case of untreated peritoneal mesothelioma. Med Jol Australia. 150:43-44, 1989
30. Antman KH: Natural history and epidemiology of malignant mesothelioma. Chest 103:373-376, 1993 (suppl)
31. Geroulanos S, Hafner F, Senning A, et al: Malignant pleural mesotheliomas. Surgical treatment and prognosis. Helvetica Chirurgica Acta 54:329-332, 1987
32. Achatzy R, Beba W, Ritschler R, et al: The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. Euro J CardioThoracic Surg 3:445-447, 1989
33. Johansson L, Linden CJ: Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 109:109-114, 1996
34. Wilson GE, Hasleton PS, Chatterjee AK: Desmoplastic malignant mesothelioma: A review of 17 cases. J Clin Pathol 45:295-298, 1992
35. Vaillat JR, Farisse P, Rey F, et al: Epidemiology and etiology of mesothelioma. Revue du Practicien 40:1842-1845, 1990